Janardhanan Rajesh, Kramer Christopher M
Department of Medicine (Cardiology), Cardiovascular Imaging Center, University of Virginia Health System, 1215 Lee St., Box 800170, Charlottesville, VA 22908, USA.
Expert Rev Cardiovasc Ther. 2011 Feb;9(2):199-209. doi: 10.1586/erc.10.190.
Hypertensive heart disease is the target organ response to arterial hypertension. Left ventricular hypertrophy represents an important predictor for cardiovascular events. Myocardial fibrosis, a common end point in hypertensive heart disease, has been linked to the development of left ventricular hypertrophy and diastolic dysfunction. Echocardiography is clinically useful in the detection of left ventricular hypertrophy and the assessment of diastolic function. Although echocardiography is more widely available, cardiac magnetic resonance has been demonstrated to be more reproducible for the estimation of left ventricular mass. Future developments in cardiac magnetic resonance techniques may facilitate the quantification of diffuse fibrosis that occurs in hypertensive heart disease. Thus, advances in cardiac imaging provide comprehensive, noninvasive tools for imaging left ventricular hypertrophy, diastolic dysfunction, myocardial fibrosis and ischemia observed in hypertensive heart disease. The objective of this article is to summarize the state-of-the-art and the future of multimodality imaging of hypertensive heart disease.
高血压性心脏病是对动脉高血压的靶器官反应。左心室肥厚是心血管事件的重要预测指标。心肌纤维化是高血压性心脏病的常见终点，与左心室肥厚和舒张功能障碍的发生有关。超声心动图在检测左心室肥厚和评估舒张功能方面具有临床实用性。虽然超声心动图应用更广泛，但心脏磁共振成像已被证明在估计左心室质量方面更具可重复性。心脏磁共振成像技术的未来发展可能有助于量化高血压性心脏病中发生的弥漫性纤维化。因此，心脏成像技术的进步为高血压性心脏病中观察到的左心室肥厚、舒张功能障碍、心肌纤维化和缺血提供了全面的非侵入性成像工具。本文的目的是总结高血压性心脏病多模态成像的现状和未来。
